PPARG and Hepatic fibrosis: PPARγ agonists had inhibitory effect on hepatic stellate cell growth in a hepatic fibrosis model [40] and PPARγ ligand also inhibited the TGF-β-mediated lung myofibroblast differentiation [41] suggesting that downregulation of PPARγ may be a profibrogenic signal.